Bivalent oral polio vaccine (bOPV) consists of live, attenuated (weakened) poliovirus strains of type 1 and type 3. It simultaneously targets the two remaining types of wild poliovirus (type 1 and type 3) and was developed to improve the efficiency and impact of vaccination campaigns in areas where both types of poliovirus co-circulate.Bivalent oral polio vaccine was first used in Afghanistan in December 2009, when 2.8 million children under five years old received the vaccine.
Bivalent oral polio vaccine offers the same advantages as OPV. In addition:
Bivalent OPV is at least 30% more effective than trivalent OPV and almost as good as the respective monovalent OPVs.
It is recommended that bOPV is introduced as rapidly as possible into supplementary immunization activities (SIAs) of all endemic countries and in some outbreak settings. The vaccine is recommended for use in SIAs to complement the ongoing large-scale use of trivalent OPV for routine immunization and SIAs, and the use of monovalent OPVs for SIAs.
The Global Polio Eradication Initiative © Copyright 2010